tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RAPT Stock Latest News

Rapt Therapeutics price target raised to $57 from $55 at JPMorgan
The FlyRapt Therapeutics price target raised to $57 from $55 at JPMorgan
6d ago
RAPT
Rapt Therapeutics price target lowered to $56 from $58 at Barclays
PremiumThe Fly
Rapt Therapeutics price target lowered to $56 from $58 at Barclays
11d ago
RAPT
RAPT Therapeutics Advances with Strong Financial Backing
PremiumCompany Announcements
RAPT Therapeutics Advances with Strong Financial Backing
11d ago
RAPT
Rapt Therapeutics shares ‘exceptionally compelling,’ says Clear Street
PremiumThe Fly
Rapt Therapeutics shares ‘exceptionally compelling,’ says Clear Street
12d ago
RAPT
Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics
PremiumRatings
Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics
12d ago
RAPT
Buy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth Plans
PremiumRatingsBuy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth Plans
12d ago
RAPT
Rapt Therapeutics reports Q3 EPS (65c), consensus (85c)
Premium
The Fly
Rapt Therapeutics reports Q3 EPS (65c), consensus (85c)
12d ago
RAPT
Rapt Therapeutics price target raised to $72 from $48 at Wells Fargo
Premium
The Fly
Rapt Therapeutics price target raised to $72 from $48 at Wells Fargo
15d ago
RAPT
Rapt Therapeutics price target raised to $72 from $27 at H.C. Wainwright
PremiumThe Fly
Rapt Therapeutics price target raised to $72 from $27 at H.C. Wainwright
22d ago
RAPT
Clear Street positive on Rapt Therapeutics into food allergy study
PremiumThe Fly
Clear Street positive on Rapt Therapeutics into food allergy study
22d ago
RAPT
Rapt Therapeutics initiates prestIgE Phase 2b trial
PremiumThe Fly
Rapt Therapeutics initiates prestIgE Phase 2b trial
22d ago
RAPT
Rapt Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Rapt Therapeutics initiated with a Buy at Guggenheim
22d ago
CHRO
RAPT
Rapt Therapeutics Advances Food Allergy Treatment with RPT904 Study
PremiumCompany AnnouncementsRapt Therapeutics Advances Food Allergy Treatment with RPT904 Study
25d ago
RAPT
RAPT Therapeutics Announces Major Public Stock Offering
Premium
Company Announcements
RAPT Therapeutics Announces Major Public Stock Offering
26d ago
8K
RAPT
Rapt Therapeutics 8.333M share Spot Secondary priced at $30.00
Premium
The Fly
Rapt Therapeutics 8.333M share Spot Secondary priced at $30.00
27d ago
RAPT
Rapt Therapeutics announces common stock offering, no amount given
PremiumThe Fly
Rapt Therapeutics announces common stock offering, no amount given
28d ago
RAPT
Rapt Therapeutics price target raised to $48 from $38 at Wells Fargo
PremiumThe Fly
Rapt Therapeutics price target raised to $48 from $38 at Wells Fargo
28d ago
RAPT
Rapt Therapeutics price target raised to $60 from $41 at Clear Street
PremiumThe Fly
Rapt Therapeutics price target raised to $60 from $41 at Clear Street
29d ago
RAPT
RAPT Therapeutics Reports Positive Phase 2 Trial Results
PremiumCompany Announcements
RAPT Therapeutics Reports Positive Phase 2 Trial Results
29d ago
8K
RAPT
Rapt Therapeutics price target raised to $58 from $35 at Barclays
PremiumThe FlyRapt Therapeutics price target raised to $58 from $35 at Barclays
29d ago
RAPT
RAPT Therapeutics’ Promising Phase 2 Results and Strategic Advancements Drive Buy Rating
Premium
Ratings
RAPT Therapeutics’ Promising Phase 2 Results and Strategic Advancements Drive Buy Rating
29d ago
RAPT
JPMorgan upgrades Rapt Therapeutics on ‘compelling’ CSU data
Premium
The Fly
JPMorgan upgrades Rapt Therapeutics on ‘compelling’ CSU data
29d ago
RAPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >